LAEKNA-B (02105) released its mid-term performance report, with other income of 25.962 million yuan, an increase of 30.41% year-on-year.

LAEKNA-B (02105) released its interim results for the six months ending June 30, 2026, reporting other income of 25.962 million yuan (Renminbi, the same below), a year-on-year increase of 30.41%; research and development expenses of 97 million yuan, a year-on-year decrease of 7.79%; and a net loss of 2.549 million yuan, a year-on-year decrease of 98.03%. The announcement stated that other income increased by 6.1 million yuan or 30.7%, from 19.90 million yuan for the six months ending June 30, 2025, to 26 million yuan for the six months ending June 30, 2026, primarily due to increased interest income from bank deposits. LAE102 is a monoclonal antibody independently developed by the company that targets ActRIIA. Blocking the Activin-ActRII pathway can promote muscle regeneration and reduce fat, making LAE102 a highly promising candidate drug for controlling weight while preserving muscle. LAE103 is a selective antibody for ActRIIB, and LAE123 is a dual antagonist monoclonal antibody for ActRIIA/IIB. Both are antibodies independently developed by the company for muscle and other disease indications. The group has established a comprehensive ActRII product portfolio, committed to maximizing the development value targeting the ActRII receptor. Currently, the company is rapidly advancing the clinical development of this portfolio while actively seeking strategic partners to accelerate its overall development and commercialization process. Additionally, the group is actively exploring potential combination treatment opportunities between pipeline products and existing approved drugs and traditional therapies. The combination trial of the company's LAE002 (afuresertib) with fulvestrant has shown significant clinical value in HR+/HER2- breast cancer patients who have previously failed standard endocrine/anti-estrogen therapy (including CDK4/6 inhibitors), an area with substantial unmet medical needs and enormous market potential. Likewise, the combination therapy of LAE002 (afuresertib) and LAE001 (lapiteronel) has also shown good therapeutic benefits in patients with metastatic castration-resistant prostate cancer (mCRPC) who are resistant to second-generation androgen/androgen receptor (A/AR) drugs. AstraZeneca's capivasertib (Truqap) is the world's first approved AKT inhibitor. Following its initial approval in November 2023 for the treatment of HR+/HER2- breast cancer, the U.S. FDA approved capivasertib (Truqap) in June 2026 for use in combination with abiraterone and prednisone for the treatment of PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). Such approvals significantly broaden the treatment scope of AKT inhibitors and highlight their potential in addressing unmet medical needs across various tumor types. The company is committed to fully unleashing the clinical potential of its pipeline products. During the reporting period, the group successfully completed the Phase I SAD study for LAE102 in collaboration with Eli Lilly in the U.S. In June 2026, the group entered into an exclusive licensing agreement with Vasque Bio, under which Vasque Bio (among other rights) was granted an exclusive license within a specified territory to develop, manufacture, commercialize, and otherwise develop LAE118. In 2025, the group entered into an exclusive licensing agreement with Qilu Pharmaceutical for LAE002 (afuresertib) in the Chinese region to accelerate the regulatory approval and commercialization process of LAE002 (afuresertib) and maximize its commercial value. Looking ahead, the company will continue to seek strategic partnerships with leading pharmaceutical companies to advance clinical development and commercialization of its candidate drug assets. In the future, the group's goal is to initiate IND-supporting research for LAE124 (a small molecule amylin and calcitonin dual receptor agonist) in 2026. The company has also obtained IND approval from the U.S. FDA and Chinas CDE for LAE118 (a PI3K pan-mutant selective inhibitor targeting PIK3CA mutations in advanced solid tumors). With the company's good track record in successfully developing and licensing LAE002 (afuresertib), it is accelerating the development of LAE118, aiming to provide this precision therapy to cancer patients in need of new treatment options. The company's continually expanding product pipeline demonstrates its commitment to bringing transformative therapies to patients globally.